|1.||Bendas, Gerd: 7 articles (12/2015 - 12/2008)|
|2.||Schlesinger, Martin: 6 articles (12/2015 - 11/2009)|
|3.||Lam, Kit S: 6 articles (05/2012 - 07/2006)|
|4.||Liu, Ruiwu: 6 articles (05/2012 - 10/2004)|
|5.||Okada, Hideho: 6 articles (10/2009 - 01/2007)|
|6.||Anderson, Carolyn J: 5 articles (06/2015 - 05/2012)|
|7.||Sasaki, Kotaro: 5 articles (10/2009 - 01/2007)|
|8.||Storkus, Walter J: 5 articles (10/2009 - 01/2007)|
|9.||Hagmann, William K: 5 articles (02/2007 - 01/2002)|
|10.||Greil, Richard: 4 articles (08/2015 - 04/2009)|
|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/01/1997 - "Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis."
02/01/2003 - "Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis."
05/01/2015 - "Here, we report that the selective inhibition of VLA-4 expression on B cells impedes CNS accumulation of B cells, and recruitment of Th17 cells and macrophages, and reduces susceptibility to experimental autoimmune encephalomyelitis. "
06/15/2010 - "Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis."
04/01/2006 - "NOS2 regulates cytokine production and VLA-4 expression in experimental autoimmune encephalomyelitis."
02/15/2006 - "These studies indicate the usefulness of antagonists of integrin alpha4beta1 in suppressing macrophage colonization of tumors and subsequent tumor angiogenesis. "
12/01/2015 - "This review gives an up to date insight into the multiple functional role of VLA-4 in cancer and introduces this integrin as a promising target worthwhile to attract attention in biomedical cancer research. "
12/01/2015 - "Nevertheless, despite accumulating evidence for several functions of VLA-4 in tumorigenicity, a therapeutic interference with VLA-4 in cancer sciences has not been developed yet to the clinical level, undoubtedly by a marked impact on the physiological immune response. "
12/01/2015 - "With a growing insight into the molecular mechanisms for creating a tumor-friendly microenvironment at metastatic sites and various tumor host interactions, the multiple functions of VLA-4 became evident recently, e.g., in leukocyte recruitment to micrometastases, the protection of tumors from immune surveillance, or contribution to a chemoresistance. "
12/01/2015 - "In addition, leukemic cells and different solid tumors, which express VLA-4, make use of these adhesive functions and confer VLA-4 a progressive role in the metastatic spread. "
05/15/1995 - "In this study we have compared various T cell high and low responder situations, and these experiments revealed that acute inflammation correlates directly with VLA-4 expression on splenic CD8+ cells. "
12/01/2015 - "Thus, VLA-4 is a valuable target in medical sciences to interfere with pathological inflammations. "
03/01/2013 - "Integrin very late antigen-4 (VLA4) is induced during inflammation and can regulate monocyte migration. "
10/15/2006 - "The alpha4beta1 integrin is an essential adhesion molecule for recruitment of circulating lymphocytes into lymphoid organs and peripheral sites of inflammation. "
06/15/2006 - "The alpha4beta1 integrin, expressed on eosinophils and neutrophils, induces inflammation in the lung by facilitating cellular infiltration and activation. "
|4.||Melanoma (Melanoma, Malignant)
02/01/2014 - "Therefore, expression of the VLA-4-stimulating factor sequence may help to predict melanoma prometastatic risk, and offers therapeutic targets for metastatic melanoma deactivation through VLA-4 activation blockade. "
06/01/2015 - "The affinity of (177)Lu- and (68)Ga-labeled DOTA-PEG4-LLP2A to VLA-4 was determined in B16F10 melanoma cells by saturation binding and competitive binding assays, respectively. "
11/01/2014 - "Saturation and competitive binding assays with B16F10 melanoma cells determined the affinity of the compounds for VLA-4. "
11/01/2014 - "PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates."
11/01/2013 - "The integrin VLA-4 is important for the metastatic dissemination of melanoma cells. "
01/01/2015 - "As migration of immune cells into the CNS is facilitated by the Very Late Antigen 4 (VLA-4) integrin molecule, the VLA4 gene may be considered as a plausible candidate genetic risk factor for susceptibility to MS. Therefore, the objective of our study was to investigate the association between two genetic polymorphisms located in the VLA4 gene and the risk of multiple sclerosis. "
01/01/2013 - "Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study."
09/01/2007 - "In multiple sclerosis (MS), alpha(4)beta(1) integrin, also known as Very Late Antigen 4 (VLA4), facilitates migration of leukocytes across the blood brain barrier. "
03/01/2011 - "Ab-mediated blockade of the adhesion molecule VLA-4 has been shown to ameliorate disease in human multiple sclerosis patients and experimental autoimmune encephalomyelitis (EAE) animal models. "
04/01/2006 - "Natalizumab, a humanized monoclonal antibody against alpha4beta1 integrin, was shown in clinical trials to dramatically reduce the relapse rate, development of new magnetic resonance imaging (MRI) lesions and progression of disability in patients with relapsing multiple sclerosis. "
|1.||Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
|5.||Lymphocyte Function-Associated Antigen-1 (LFA-1)
|10.||Apolipoproteins E (ApoE)
|1.||Drug Therapy (Chemotherapy)
|3.||Homologous Transplantation (Allograft)